Glaucoma Research Foundation

National Glaucoma Research Foundation Survey Reveals Glaucoma Patients’ Experiences and Concerns During COVID-19 Pandemic

Findings from survey of more than 1,000 Americans suggest one-third lacked confidence that their disease was well-managed during early phase of lockdowns.
14-Jul-2020 12:05 PM EDT, by Glaucoma Research Foundation

Newswise — SAN FRANCISCO, July 14, 2020 – Glaucoma Research Foundation (GRF), a national non-profit organization dedicated to finding a cure for glaucoma, announced results from a survey designed to explore glaucoma patients’ experiences and concerns during the COVID-19 pandemic-related shutdowns. The survey, conducted among patients in the GRF database and supported by Aerie Pharmaceuticals, is intended to help inform care as the response to COVID-19 continues to evolve and eye care offices adapt to new patient-care requirements. 

A total of 1,051 adult glaucoma patients from 49 states responded to the online National COVID-19 Glaucoma Impact Survey over four days in May 2020. Findings suggest that about one-third of glaucoma patients were not confident that their disease was well-managed during the initial months of the pandemic (36 percent “somewhat confident” or “not confident”). Confidence level was not associated with patients’ age, gender or geography, but was most significantly affected by appointment status. 

Overall, more than half of the patients (53 percent) surveyed said they had to delay and/or cancel a glaucoma appointment during the first months of the pandemic. Patients who had the lowest levels of confidence regarding their glaucoma management were 30 percent more likely to have had an eye care appointment delayed and/or cancelled as compared to patients with higher levels of confidence.

“Glaucoma patients and their eye care professionals have faced particular challenges during the COVID-19 pandemic closures, given the progressive but indolent nature of a disease that can lead to blindness and the fact that tests required to monitor eye pressure or detect disease progression must be performed in person,” said Thomas Brunner, GRF president and CEO. “We hope the findings from this survey provide valuable perspective to eye care professionals regarding their patients’ preferences, concerns and experiences as they are able to re-open their offices and begin advancing glaucoma care.” 

In addition to patients’ confidence in their disease management during the pandemic, the GRF survey assessed patients’ specific disease-management concerns, their experiences and comfort with telemedicine, how the pandemic impacted medication availability and adherence, and patients’ comfort returning to their eye care professionals’ offices. 

Key survey findings related to patients’ experiences during the pandemic include:

  • From among six potential concerns suggested in the survey, patients worried most about:
    • Vision getting worse/losing vision (13 percent “very worried” or “extremely worried”)
    • Not being able to have an appointment with an eye doctor in person (12 percent “very worried” or “extremely worried”)
    • Not being able to have a quality appointment with an eye doctor due to social distancing and face masks (12 percent “very worried” or “extremely worried”)
    • Not having good control of intraocular pressure (10 percent “very worried” or “extremely worried”)
  • Telemedicine was not widely offered or embraced during the first seven weeks of the pandemic lockdowns (i.e., mid-March to early May). Among the 1,051 patients surveyed, just 4 percent were offered telemedicine visits, and fewer than 3 percent accepted. This may be a result of patients’ strong preference for in-person office visits, as well as a lack of technology – either for patients to participate in virtual visits or for physicians to perform specific eyecare tests remotely.
    • Sixty-eight percent of patients say that once offices re-open, they prefer to be seen in person. Just 4 percent prefer a telemedicine visit. The remaining 28 percent said they will only be seen via telemedicine if their eye doctor asks them to consider it.
    • Given a choice between waiting six weeks for an in-person appointment and being seen via telemedicine in two weeks, 87 percent of survey participants preferred to wait for an in-person visit.
  • Respondents’ access to glaucoma medication and adherence to their treatment regimen did not appear to be impacted during this period. Patients maintained their supply of medication by refilling prescriptions early and/or receiving longer prescriptions (e.g., 90-day supply), and did not report rationing. 

“A percentage of patients clearly struggled with the inability to see their eye care professional during the lockdowns, but it is reassuring to know that many of our patients were not overly worried about vision loss during this period and nearly all were able to adhere to their treatment regimens,” said Andrew Iwach, MD, GRF board chair and executive director, Glaucoma Center of San Francisco. “It’s also helpful to have patients’ input regarding the measures we can put in place to maintain or increase their confidence and comfort as we return to more in-person visits. Eye care professionals are making significant changes to keep patients and staff safe, but the survey findings help us understand what may help them feel safe too.” 

Nearly two-thirds of patients who responded to the GRF survey said they are comfortable returning to their eye doctors’ offices (63 percent “somewhat comfortable” or “extremely comfortable”), assuming certain precautions are in place – most importantly face masks and less crowded waiting rooms. Survey respondents are comfortable waiting an average of five weeks after offices re-open to see their physician in person. 

“We are grateful for the opportunity to help GRF and eye care professionals understand how the COVID-19 pandemic has impacted glaucoma patients in this country and how best to serve them as they begin returning to our offices,” said Richard Lewis, M.D., chief medical officer, Aerie Pharmaceuticals, and a practicing glaucoma specialist. “Our support for this survey is part of Aerie’s ongoing commitment to nurturing the physician-patient relationship, which is central to enhancing glaucoma care.”


About the National COVID-19 Glaucoma Impact Survey

Glaucoma Research Foundation (GRF), with support from Aerie Pharmaceuticals, commissioned a national survey of glaucoma patients to assess experiences and concerns during the COVID-19 pandemic. Outcomes Insights conducted the survey on behalf of GRF between May 7 and May 11, 2020, and a total of 1,051 glaucoma patients completed it. All survey participants were age 18 or older.


About Glaucoma

Glaucoma is the second leading cause of blindness in the world, and vision loss from glaucoma is irreversible. Currently there is no cure, and everyone is at risk for developing this blinding disease. It is estimated that by 2040, 111 million people worldwide will have glaucoma.


About Glaucoma Research Foundation

Glaucoma Research Foundation (GRF) is a national non-profit organization dedicated to finding a cure for glaucoma. For more than 40 years, Glaucoma Research Foundation has worked to advance sight-saving research and provide essential educational resources for patients. It funds critical research into glaucoma treatment, vision restoration, and a cure for glaucoma. It is also the leading source of information for glaucoma patients and their families. For more information, visit



The National COVID-19 Glaucoma Impact Survey was supported by Aerie Pharmaceuticals.



# # #




Filters close

Showing results

110 of 2776
Newswise:Video Embedded protocol-needed-to-monitor-covid-19-disease-course
Released: 3-Aug-2020 9:05 PM EDT
Protocol needed to monitor COVID-19 disease course
University of Washington School of Medicine and UW Medicine

Patients with underlying conditions such as asthma or other lung problems should be checked on regularly by pulmonologists or primary-care doctors for at least six months. Some will need to be monitored for one to three years, according to a new opinion piece posted online today in The Lancet-Respiratory Medicine.

Newswise: UM Cardiology Researchers Studying How COVID-19 Affects the Heart
Released: 3-Aug-2020 3:10 PM EDT
UM Cardiology Researchers Studying How COVID-19 Affects the Heart
University of Miami Health System, Miller School of Medicine

COVID-19 is shown to impact the heart and, in some cases, have long-lasting cardiac effects. To discover the extent to which COVID-19 affects the heart, cardiologists and researchers with the University of Miami Miller School of Medicine have begun multiple studies.

Newswise: Tackling the Bioethics Challenges Raised by COVID-19
Released: 3-Aug-2020 3:05 PM EDT
Tackling the Bioethics Challenges Raised by COVID-19
University of Pennsylvania School of Nursing

The diverse situations experienced by health-care workers during the COVID-19 pandemic often present serious ethical challenges. From the allocation of resources and triage protocols to health-care worker and patient rights and the management of clinical trials, new ethical questions have come to the forefront of today’s global public health emergency.

Newswise: 239156_web.jpg
Released: 3-Aug-2020 2:50 PM EDT
New species of fungus sticking out of beetles named after the COVID-19 quarantine
Pensoft Publishers

A major comprehensive study on Herpomycetales and Laboulbeniales, two orders of unique ectoparasitic fungi associated with insects and other arthropods (class Laboulbeniomycetes) in Belgium and the Netherlands was published in the open-access, peer-reviewed scholarly journal MycoKeys.

Released: 3-Aug-2020 1:30 PM EDT
Consumer Behavior Has Shifted Significantly During Pandemic, Survey Reveals
Rensselaer Polytechnic Institute (RPI)

The COVID-19 pandemic has brought about an increase in telework and online commerce, and a significant decrease in the number of personal trips people are making. Understanding the effects of these rapid changes on the economy, supply chains, and the environment will be essential, as some of these behaviors will continue even after the pandemic has ended. Researchers from Rensselaer Polytechnic Institute recently presented the results of two sets of surveys they conducted in an effort to quantify and understand these unprecedented shifts.

access_time Embargo lifts in 2 days
Embargo will expire: 5-Aug-2020 12:05 AM EDT Released to reporters: 3-Aug-2020 12:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 5-Aug-2020 12:05 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

31-Jul-2020 4:05 PM EDT
The effects of COVID-19 on emergency visits, hospitalizations
Mayo Clinic

COVID-19 swept into the U.S., hospitals across the country have reported that their emergency departments are emptying out. In a new study published Monday, Aug. 3, in JAMA Internal Medicine, a team of researchers from multiple institutions provides insights into this phenomenon.

Newswise: Important Dementia Studies Continuing at UK Despite Ongoing COVID-19 Pandemic
Released: 3-Aug-2020 10:20 AM EDT
Important Dementia Studies Continuing at UK Despite Ongoing COVID-19 Pandemic
University of Kentucky

The COVID-19 pandemic brought many things to a screeching halt and continues to impact our daily lives. However, important research at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) is continuing under extreme caution and deep dedication. A monumental study in the field of dementia research is set to get underway in the coming weeks at UK.

Showing results

110 of 2776